AC Immune’s (ACIU) Buy Rating Reiterated at BTIG Research

AC Immune (NASDAQ:ACIU)‘s stock had its “buy” rating reiterated by BTIG Research in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $8.00 price objective on the stock. BTIG Research’s price objective suggests a potential upside of 195.75% from the stock’s previous close.

Several other equities research analysts have also issued reports on ACIU. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of AC Immune in a research report on Wednesday, August 5th. HC Wainwright reissued a “buy” rating on shares of AC Immune in a report on Monday, August 24th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $7.50.

AC Immune Stock Performance

Shares of AC Immune stock traded down $0.13 during trading hours on Wednesday, hitting $2.71. 69,774 shares of the company’s stock traded hands, compared to its average volume of 273,762. AC Immune has a 12-month low of $2.10 and a 12-month high of $4.00. The stock has a market capitalization of $275.29 million, a price-to-earnings ratio of -5.01 and a beta of 1.60. The company has a fifty day simple moving average of $2.55 and a 200-day simple moving average of $2.68. The company has a debt-to-equity ratio of 0.11, a current ratio of 0.93 and a quick ratio of 1.02.

AC Immune (NASDAQ:ACIU) last announced its earnings results on Thursday, August 6th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.13. AC Immune had a negative return on equity of 100.17% and a negative net margin of 245.32%.The firm had revenue of $18.67 million during the quarter, compared to analyst estimates of $9.59 million. Equities research analysts anticipate that AC Immune will post -0.6 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. AXQ Capital LP bought a new stake in shares of AC Immune during the 2nd quarter valued at about $25,000. Arrowstreet Capital Limited Partnership boosted its position in shares of AC Immune by 8.0% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 405,658 shares of the company’s stock valued at $1,116,000 after acquiring an additional 30,035 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of AC Immune by 82.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 390,165 shares of the company’s stock valued at $1,071,000 after acquiring an additional 176,701 shares during the last quarter. Hedge funds and other institutional investors own 51.36% of the company’s stock.

Key Headlines Impacting AC Immune

Here are the key news stories impacting AC Immune this week:

• Positive Sentiment: Positive Phase 2 results support the platform. In Part 1 of the VacSYn Phase 2 trial, ACI-7104 met all primary safety and immunogenicity endpoints through week 100. The company reported that the treatment was generally safe and well tolerated, produced a 100% antibody response after three immunizations, showed antibody penetration into cerebrospinal fluid, and generated signals of target engagement. AC Immune Reports Positive Safety and Immunogenicity at Week 100
• Positive Sentiment: Analysts maintained bullish views and high price targets. BTIG Research reaffirmed its Buy rating and assigned an $8.00 target, while H.C. Wainwright analyst Andrew Fein maintained a Buy rating and a $12.00 target. The targets imply substantial potential upside if ACI-7104 advances successfully through development. BTIG Reaffirms Buy Rating on AC Immune H.C. Wainwright Maintains Buy Rating and Price Target
• Neutral Sentiment: Important development milestones remain ahead. Part 1 primarily evaluated safety and immune response; Part 2 is intended to provide evidence of clinical activity and inform a potential Phase 3 decision. AC Immune expects to discuss the future development path with the FDA in early 2027, so clinical efficacy and regulatory risk remain unresolved.

AC Immune Company Profile

AC Immune SA (NASDAQ: ACIU) is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland. Founded in 2003, the company develops precision medicines and diagnostic products designed to prevent, diagnose and treat neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease and other conditions associated with misfolded proteins.

AC Immune’s research is based on its SupraAntigen and Morphomer technology platforms, which are intended to identify disease-related proteins and generate therapies or diagnostic tools that target them.